drugset
drugset / Trial / NCT05584761

Unrelated Umbilical Cord Blood Stem Cell Combined With Azacitidine Based Treatment for Advanced MDS,CMML-2 and sAML

NCT05584761 ↗

Phase 1/2 Recruiting 50 enrolled The First Affiliated Hospital with Nanjing Medical University
NaSingle-groupOpen-labelTreatment

Summary

This research is being done to study the efficacy and safety of unrelated umbilical cord blood stem cell microtransplantation combined with azacitidine(AZA) based treatment for advanced myelodysplastic syndromes(MDS), Chronic myelomonocytic leukemia-2(CMML-2) and secondary acute myeloid leukemia(sAML). The study protocol involved unrelated umbilical cord blood stem cell combined with azacitidine based treatment, which including azacitidine alone and azacitidine plus a targeted agent or chemotherapy agent.

Timeline

Start
2022-03-01
Primary completion
2026-12-31
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Azacitidine Other / unclassified 75 mg/m2 Subcutaneous
Subject Homoharringtonine Small molecule — Intravenous
Subject Unrelated Umbilical Cord Blood Cell therapy — Other
Subject Venetoclax Small molecule 400 mg Oral

Indications

acute myeloid leukemia chronic myelomonocytic leukemia myelodysplastic syndrome